

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Leukemia Market to 2018 - Introduction

3 Leukemia Market to 2018 - Market Overview

3.1 Introduction

3.1.1 Revenue

3.1.2 Annual Cost of Treatment

3.1.3 Treatment Usage Pattern

3.2 Drivers and Barriers

3.2.1 Drivers for the Leukemia Therapeutics Market

3.2.2 Barriers for the Leukemia Therapeutics Market

4 Leukemia Market to 2018 - Geographical Landscape

4.1 Revenue Analysis by Geography

4.2 The US

4.2.1 Revenue

4.2.2 Annual Cost of Therapy

4.2.3 Treatment Usage Pattern

4.3 Top Five Countries of Europe

4.3.1 Revenue

4.3.2 Annual Cost of Therapy

4.3.3 Treatment Usage Pattern

4.4 Japan

4.4.1 Revenue

4.4.2 Annual Cost of Therapy

4.4.3 Treatment Usage Pattern

5 Leukemia Market to 2018 - Therapeutic Landscape

5.1 Acute Lymphocytic Leukemia (ALL) Therapeutics Market

5.1.1 Introduction

5.1.2 Classification

5.1.3 Epidemiology

5.1.4 Signs and Symptoms

5.1.5 Treatment and Management Pattern

5.1.6 Revenue

5.1.7 Annual Cost of Treatment

5.1.8 Treatment Usage Pattern

5.1.9 Major Marketed Products

5.1.10 Drivers and Barriers for the ALL Therapeutics Market

5.2 Chronic Lymphocytic Leukemia Therapeutics Market

5.2.1 Introduction

5.2.2 Epidemiology

5.2.3 Symptoms

5.2.4 Diagnosis

5.2.5 Treatment

5.2.6 Revenue

5.2.7 Annual Cost of Treatment

- 5.2.8 Treatment Usage Pattern
- 5.2.9 Major Marketed Products
- 5.2.10 Drivers and Barriers for the CLL Therapeutics Market
- 5.3 Acute Myelogenous Leukemia Therapeutics Market
 - 5.3.1 Introduction
 - 5.3.2 Epidemiology
 - 5.3.3 Symptoms
 - 5.3.4 Staging of AML
 - 5.3.5 Diagnosis
 - 5.3.6 Treatment by Stage
 - 5.3.7 Revenue
 - 5.3.8 Annual Cost of Treatment
 - 5.3.9 Treatment Usage Pattern
 - 5.3.10 Major Marketed Products
 - 5.3.11 Drivers and Barriers for the AML Therapeutics Market
- 5.4 Chronic Myelogenous Leukemia Therapeutics Market
 - 5.4.1 Introduction
 - 5.4.2 Epidemiology
 - 5.4.3 Staging
 - 5.4.4 Symptoms
 - 5.4.5 Diagnosis
 - 5.4.6 Treatment of CML
 - 5.4.7 Revenue
 - 5.4.8 Annual Cost of Treatment
 - 5.4.9 Treatment Usage Pattern
 - 5.4.10 Major Marketed Products
 - 5.4.11 Drivers and Barriers for the CML Therapeutics Market

6 Leukemia Market to 2018 - Pipeline Analysis

- 6.1 Introduction
- 6.2 Pipeline Assessment by Indication
 - 6.2.1 Acute Lymphocytic Leukemia
 - 6.2.2 Chronic Lymphocytic Leukemia
 - 6.2.3 Acute Myelogenous Leukemia
 - 6.2.4 Chronic Myelogenous Leukemia
- 6.3 Profiles of Promising Molecules for Leukemia
 - 6.3.1 DepoCyte (liposomal cytarabine)
 - 6.3.2 GRASPA (L-asparaginase)
 - 6.3.3 Marqibo (vincristine sulfate liposomes injection)
 - 6.3.4 GA101 (Obinutuzumab, RO5072759, RG7159)
 - 6.3.5 Revlimid (lenalidomide)
 - 6.3.6 Clolar (clofarabine)
 - 6.3.7 Dacogen (decitabine)
 - 6.3.8 Midostaurin (PKC 412)
 - 6.3.9 Quizartinib (AC220)
 - 6.3.10 Sapacitabine
 - 6.3.11 Tosedostat (CHR-2797)

- 6.3.12 Vidaza (azacitadine)
- 6.3.13 Vosaroxin
- 6.3.14 Omapro (omacetaxine mepesuccinate)
- 6.3.15 Bosutinib (SKI-606)

7 Leukemia Market to 2018 - Competitive Landscape

- 7.1 Novartis AG
 - 7.1.1 Company Overview
 - 7.1.2 SWOT Analysis
- 7.2 GlaxoSmithKline plc (GSK)
 - 7.2.1 Company Overview
 - 7.2.2 SWOT Analysis
- 7.3 Genzyme Corporation
 - 7.3.1 Company Overview
 - 7.3.2 SWOT Analysis
- 7.4 Bristol-Myers Squibb Company (BMS)
 - 7.4.1 Company Overview
 - 7.4.2 SWOT Analysis
- 7.5 Eisai Co., Ltd.
 - 7.5.1 Company Overview
 - 7.5.2 SWOT Analysis

8 Leukemia Market to 2018 - Strategic Consolidations

- 8.1 Analysis by Deal Type
- 8.2 Analysis by Indication
- 8.3 Mergers & Acquisitions
 - 8.3.1 Segmentation by Year
 - 8.3.2 Segmentation by Geography
 - 8.3.3 Segmentation by Value
 - 8.3.4 Major Mergers and Acquisitions
- 8.4 Licensing Agreements
 - 8.4.1 Segmentation by Year
 - 8.4.2 Segmentation by Geography
 - 8.4.3 Segmentation by Value
 - 8.4.4 Major Licensing Agreements
- 8.5 Co-development Deals
 - 8.5.1 Segmentation by Year
 - 8.5.2 Segmentation by Geography
 - 8.5.3 Segmentation by Value
 - 8.5.4 Major Co-Development Deals

9 Leukemia Market to 2018 - Appendix

- 9.1 Market Definitions
- 9.2 Abbreviations
- 9.3 Bibliography
- 9.4 Research Methodology
 - 9.4.1 Coverage
 - 9.4.2 Secondary Research
 - 9.4.3 Primary Research

- 9.4.4 Therapeutic Landscape
- 9.4.5 Market Size by Geography
- 9.4.6 Geographical Landscape
- 9.4.7 Pipeline Analysis
- 9.4.8 Competitive Landscape
- 9.4.9 Expert Panel Validation
- 9.5 Contact Us
- 9.6 Disclaimer

1.1 List of Tables

- Table 1: Leukemia Market to 2018, Global, Revenue (\$bn), 2004-2011
- Table 2: Leukemia Market to 2018, Global, Revenue Forecasts (\$bn), 2011-2018
- Table 3: Leukemia Market to 2018, Global, Annual Cost of Treatment (\$), 2004-2011
- Table 4: Leukemia Market to 2018, Global, Annual Cost of Treatment Forecasts (\$), 2011-2018
- Table 5: Leukemia Market to 2018, Global, Treatment Usage Pattern, Population (thousand), 2004-2011
- Table 6: Leukemia Market to 2018, Global, Treatment Usage Pattern, Population (thousand) Forecasts, 2011-2018
- Table 7: Leukemia Market to 2018, Global, Revenue, By Country (\$m), 2004-2011
- Table 8: Leukemia Market to 2018, Global, Revenue Forecasts, By Country (\$m), 2011-2018
- Table 9: Leukemia Market to 2018, The US, Revenue (\$m), 2004-2011
- Table 10: Leukemia Market to 2018, The US, Revenue Forecasts (\$m), 2011-2018
- Table 11: Leukemia Market to 2018, The US, Annual Cost of Treatment (\$), 2004-2011
- Table 12: Leukemia Market to 2018, The US, Annual Cost of Treatment Forecasts (\$), 2011-2018
- Table 13: Leukemia Market to 2018, The US, Treatment Usage Pattern, Population (thousand), 2004-2011
- Table 14: Leukemia Market to 2018, The US, Treatment Usage Pattern, Population (thousand) Forecasts, 2011-2018
- Table 15: Leukemia Market to 2018, Top Five Countries of Europe, Revenue (\$m), 2004-2011
- Table 16: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts (\$m), 2011-2018
- Table 17: Leukemia Market to 2018, Top Five Countries of Europe, Revenue, By Country (\$m), 2004-2011
- Table 18: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts, By Country (\$m), 2011-2018
- Table 19: Leukemia Market to 2018, Top Five Countries of Europe, Annual Cost of Treatment (\$), 2004-2011
- Table 20: Leukemia Market to 2018, Top Five Countries of Europe, Annual Cost of Treatment (\$) Forecasts, 2011-2018
- Table 21: Leukemia Market to 2018, Top Five Countries of Europe, Treatment Usage Pattern, Population (thousand), 2004-2011
- Table 22: Leukemia Market to 2018, Top Five Countries of Europe, Treatment Usage Pattern, Population (thousand), 2011-2018

Table 23: Leukemia Market to 2018, Japan, Revenue (\$m), 2004-2011

Table 24: Leukemia Market to 2018, Japan, Revenue Forecasts (\$m), 2011-2018

Table 25: Leukemia Market to 2018, Japan, Annual Cost of Treatment (\$), 2004-2011

Table 26: Leukemia Market to 2018, Japan, Annual Cost of Treatment (\$), 2011-2018

Table 27: Leukemia Market to 2018, Japan, Treatment Usage Pattern, Population, 2004-2011

Table 28: Leukemia Market to 2018, Japan, Treatment Usage Pattern, Population Forecasts, 2011-2018

Table 29: Leukemia Market to 2018, Acute Lymphocytic Leukemia, FAB Classification, 2012

Table 30: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Incidence Rate by Age, 2007

Table 31: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Incidence Rates by Race, 2007

Table 32: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Treatment: Targeted Chemotherapy

Table 33: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue (\$m), 2004-2011

Table 34: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue Forecasts (\$m), 2011-2018

Table 35: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue By Country (\$m), 2004-2011

Table 36: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue Forecast By Country (\$m), 2011-2018

Table 37: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Annual Cost of Treatment (\$), 2004-2011

Table 38: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Annual Cost of Treatment Forecasts (\$), 2011-2018

Table 39: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Treatment Usage Pattern, 2004-2011

Table 40: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Treatment Usage Pattern, 2011-2018

Table 41: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Rai Staging System, The US, 2012

Table 42: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Binet Staging System, Europe, 2012

Table 43: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue (\$m), 2004-2011

Table 44: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue Forecasts (\$m), 2011-2018

Table 45: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue by Country (\$m), 2004-2011

Table 46: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue Forecasts by Country (\$m), 2011-2018

Table 47: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Annual Cost of Treatment (\$), 2004-2011

Table 48: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Annual Cost of Treatment (\$), 2011-2018

Table 49: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2011

Table 50: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2011-2018

Table 51: Leukemia Market to 2018, WHO Classification of AML, 2012

Table 52: Leukemia Market to 2018, The French-American-British (FAB) Classification of AML, 2012

Table 53: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue (\$m), 2004-2011

Table 54: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue Forecasts (\$m), 2011-2018

Table 55: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue by Country (\$m), 2004-2011

Table 56: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue by Country (\$m), 2011-2018

Table 57: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Annual Cost of Treatment (\$), 2004-2011

Table 58: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Annual Cost of Treatment (\$), 2011-2018

Table 59: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2011

Table 60: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2011-2018

Table 61: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Diagnosis Percentage by Age Group, 2004-2008

Table 62: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue (\$bn), 2004-2011

Table 63: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue Forecasts, (\$bn), 2011-2018

Table 64: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue by Country (\$m), 2004-2011

Table 65: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue by Country (\$m), 2011-2018

Table 66: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Annual Cost of Treatment (\$), 2004-2011

Table 67: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Annual Cost of Treatment (\$), 2011-2018

Table 68: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2011

Table 69: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2011-2018

Table 70: Leukemia Market to 2018, Global, Mergers and Acquisitions, 2009-2011

Table 71: Leukemia Market to 2018, Global, Licensing Agreements, 2009-2011

Table 72: Leukemia Market to 2018, Global, Co-Development Deals, 2009-2011

1.2 List of Figures

- Figure 1: Leukemia Market to 2018, Global, Revenue Forecasts (\$bn), 2004-2018
- Figure 2: Leukemia Market to 2018, Global, Branded vs. Generics (%), 2011-2018
- Figure 3: Leukemia Market to 2018, Global, Annual Cost of Treatment (\$), 2004-2018
- Figure 4: Leukemia Market to 2018, Global, Treatment Usage Pattern, Population (thousand), 2004-2018
- Figure 5: Leukemia Market to 2018, Global, Drivers and Barriers
- Figure 6: Leukemia Market to 2018, Global, Revenue Forecasts, By Country (\$m), 2004-2018
- Figure 7: Leukemia Market to 2018, The US, Revenue Forecasts (\$m), 2004-2018
- Figure 8: Leukemia Market to 2018, The US, Annual Cost of Treatment (\$), 2004-2018
- Figure 9: Leukemia Market to 2018, The US, Treatment Usage Pattern, Population (thousand), 2004-2018
- Figure 10: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts (\$m), 2004-2018
- Figure 11: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts, By Country (\$m), 2004-2018
- Figure 12: Leukemia Market to 2018, Top Five Countries of Europe, Annual Cost of Treatment (\$), 2004-2018
- Figure 13: Leukemia Market to 2018, Top Five Countries of Europe, Treatment Usage Pattern, Population (thousand), 2004-2018
- Figure 14: Leukemia Market to 2018, Japan, Revenue Forecasts (\$m), 2004-2018
- Figure 15: Leukemia Market to 2018, Japan, Annual Cost of Treatment (\$), 2004-2018
- Figure 16: Leukemia Market to 2018, Japan, Treatment Usage Pattern, Population, 2004-2018
- Figure 17: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue Forecasts (\$m), 2004-2018
- Figure 18: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue By Country (\$m), 2004-2018
- Figure 19: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Branded vs. Generics (%), 2011-2018
- Figure 20: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Annual Cost of Treatment (\$), 2004-2018
- Figure 21: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Treatment Usage Pattern, 2004-2018
- Figure 22: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Drivers and Barriers
- Figure 23: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue Forecasts (\$m), 2004-2018
- Figure 24: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue by Country (\$m), 2004-2018
- Figure 25: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Branded vs. Generics (%), 2011-2018
- Figure 26: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Annual Cost of Treatment (\$), 2004-2018

Figure 27: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2018

Figure 28: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Drivers and Barriers

Figure 29: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue Forecasts (\$m), 2004-2018

Figure 30: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue by Country (\$m), 2004-2018

Figure 31: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Branded vs. Generics (%), 2011-2018

Figure 32: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Annual Cost of Treatment (\$), 2004-2018

Figure 33: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2018

Figure 34: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Drivers and Barriers

Figure 35: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Different Stages of CML

Figure 36: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue (\$bn), 2004-2018

Figure 37: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue by Country (\$m), 2004-2018

Figure 38: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Branded vs. Generics (%), 2004-2018

Figure 39: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Annual Cost of Treatment (\$), 2004-2018

Figure 40: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2018

Figure 41: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Drivers and Barriers

Figure 42: Leukemia Market to 2018, Global, R&D Pipeline by Indications, 2011

Figure 43: Leukemia Market to 2018, Global, R&D Pipeline by Phase, 2011

Figure 44: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, R&D Pipeline, 2011

Figure 45: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, R&D Pipeline, 2011

Figure 46: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, R&D Pipeline, 2011

Figure 47: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, R&D Pipeline, 2011

Figure 48: Leukemia Market to 2018, Novartis AG, SWOT, 2011

Figure 49: Leukemia Market to 2018, GlaxoSmithKline Plc, SWOT, 2011

Figure 50: Leukemia Market to 2018, Genzyme Corporation, SWOT, 2011

Figure 51: Leukemia Market to 2018, Bristol-Myers Squibb Company, SWOT, 2011

Figure 52: Leukemia Market to 2018, Eisai Co., Ltd., SWOT, 2011

Figure 53: Leukemia Market to 2018, Global, All Deals, by Type, 2009-2011

Figure 54: Leukemia Market to 2018, Global, All Deals, By Indication, 2009-2011

Figure 55: Leukemia Market to 2018, Global, Mergers and Acquisitions, By Year, 2009-2011

Figure 56: Leukemia Market to 2018, Global, Mergers and Acquisitions, By Geography, 2009-2011

Figure 57: Leukemia Market to 2018, Global, Mergers and Acquisitions, By Value, 2009-2011

Figure 58: Leukemia Market to 2018, Global, Licensing Agreements, By Year, 2009-2011

Figure 59: Leukemia Market to 2018, Global, Licensing Agreements, By Geography, 2009-2011

Figure 60: Leukemia Market to 2018, Global, Licensing Agreements, By Value, 2009-2011

Figure 61: Leukemia Market to 2018, Global, Co-development Deals, By Year, 2009-2011

Figure 62: Leukemia Market to 2018, Global, Co-Development Deals, By Geography, 2009-2011

Figure 63: Leukemia Market to 2018, Global, Co-Development Deals, By Value, 2009-2011

Figure 64: GBI Research Market Forecasting Model